

Curriculum Vitae

Personal information

Name and surname: Doris Barcellona

Education and training

Specialization in Internal Medicine on 11.11.1997 at the University of Cagliari, with a final grade of 50/50 cum laude. Specialization thesis entitled: "Warfarin and Acenocoumarol: which to choose for better control of chronic oral anticoagulant therapy".

From March 15, 2002 to March 31, 2024, University Researcher, full-time, indefinitely, competitive sector 06/B1, S.S.D. MED/09 – Internal Medicine, in the Department of Medical Sciences and Public Health of the University of Cagliari. Confirmed Researcher in 2005.

On 7 February 2022, achievement of the National Scientific Qualification for the functions of University Professor of Second Level in the Competition Sector 06/B1 – Scientific Disciplinary Sector MED09.

From 1 April 2024, Associate Professor competitive sector 06/B1, S.S.D. MED/09 – Internal Medicine, in the Department of Medical Sciences and Public Health of the University of Cagliari.

On 24 October 2023, achievement of the National Scientific Qualification for the functions of Full-Level University Professor in the Competition Sector 06/B1 – Scientific Disciplinary Sector MED/09.

Institutional roles

Since May 2018, for the three-year period 2018-2021, by appointment of the Department Director, Prof. Giorgio La Nasa, member of the Board of the Department of Medical Sciences and Public Health of the University of Cagliari.

Confirmed member of the Board of the Department for the three-year period 2021-2024.

From 1 April 2019 to date, member of the Teaching Board of the PhD in "Sciences and Technologies for Innovation" of the University of Cagliari. Academic Year of start: 2019/2020 Cycle: 36.

For the Academic Year 2022-2023, 2023-2024 and 2024-2025 member of the teaching staff of the Master of II level in Haemostasis and Thrombosis. The Master, in collaboration with Siset (Italian Society for the Study of Hemostasis and Thrombosis), is inter-university with the Catholic University of the Sacred Heart of Rome as leader and the University of Foggia as associate university.

Teaching activity

From the Academic Year 1993 to the Academic Year 1997, tutoring activities, theoretical-practical exercises, for the students of the Faculty of Medicine and Surgery of the fourth year, within the teaching of Clinical Methodology of Prof. Francesco Marongiu.

From the Academic Year 2003-2004 to the Academic Year 2008-2009: teaching in the Integrated Course of Internal Medicine II, even channel, University of Cagliari (4 hours).

In the Academic Year 2011-2012, teaching in the Integrated Course of Internal Medicine II, odd channel, University of Cagliari (4 hours).

From the Academic Year 2006-2007 to the Academic Year 2009-2010 teaching of Internal Medicine, Degree Course in Biomedical Laboratory Techniques, University of Cagliari (10 hours).

From the Academic Year 2006-2007 to the Academic Year 2012-2013 teaching of Internal Medicine, Degree Course in Medical Radiology Techniques for Imaging and Radiotherapy, University of Cagliari, (8 hours).

From the Academic Year 2006-2007 to date, teaching of Complements of General Medicine and Surgery (from 2011 Complements of Internal Medicine), Degree Course in Biomedical Engineering, University of Cagliari, (20 hours).

From the Academic Year 2020-2021 to date, teaching, as Coordinator of the Integrated Course, of Internal Medicine and Elements of Semiotics, (Cagliari location), Degree Course in Nursing, University of Cagliari, (24 hours).

In the Academic Year 2023-2024, teaching, of Internal Medicine, Degree Course in Dentistry, University of Cagliari, (40 hours).

From the Academic Year 2024-2025 to date, teaching, as Coordinator of the Integrated Course, of Internal Medicine and Elements of Semiotics, (Nuoro campus), Degree Course in Nursing, University of Cagliari, (24 hours).

From the Academic Year 2024-2025 to date, teaching of Clinical Methodology, Degree Course in Medicine and Surgery, University of Cagliari, (40 hours).

From the Academic Year 2003-2004 to date, member, as supervisor and counter-supervisor, of the Commission for Degree Theses in the Degree Course in Medicine and Surgery of the University of Cagliari.

From the Academic Year 2008-2009 to date, member, as supervisor and counter-supervisor, of the Commission for Degree Theses in the Degree Course in Biomedical Engineering of the University of Cagliari.

Research activities

Funded projects

In 1998, participation as a collaborator in the Health Education Project, headed by Prof. Francesco Marongiu, funded by the Health Department of the Sardinia Region, entitled "Optimization of monitoring of patients treated with oral anticoagulants (warfarin) for the primary and secondary prevention of venous and arterial thrombosis. Prediction of bleeding episodes by plasma dosage of warfarin and vitamin K".

In 2003, participation as a collaborator in the Health Education Project, headed by Prof. Francesco Marongiu, funded by the Health Department of the Sardinia Region, entitled "Evaluation of congenital and acquired thrombophilia in the Sardinian population in reference to deep vein thrombosis and pulmonary embolism. In 2005, participation as a collaborator in the Health Education Project, headed by Prof. Francesco Marongiu, funded by the Health Department of the Sardinia Region, entitled "Oral anticoagulant therapy via the web: a new management project for outpatients and self-testing patients".

In 2007, participation as an experimenter for the University of Cagliari, in the PRIN (Project of Relevant National Interest) of the Universities of Padua, Milan, Perugia and Cagliari entitled: "Treatment of patients with life-threatening anti-phospholipid antibody syndrome by adsorption of pathogenic anti- β 2 Glycoprotein I domain I antibodies on affinity columns. Evaluation of the in vitro effect of adsorbed antibodies on thrombinogenesis, annexin V resistance and fibrinolysis, as well as on platelet and endothelial function".

Collaborative studies

Participation as co-investigator in the multicenter study entitled "Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation". *Circulation* 2011; 124: 824-29.

Participation as co-investigator in the multicenter study entitled "The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study". *J Thromb Haemost* 2013; 11: 1053-58.

Participation as co-investigator in the multicenter observational study entitled "The Italian START-Register on anticoagulation with focus on atrial fibrillation". *PLoS One* 2015; 10: e0124719.

Participation as co-investigator in the international multicenter study entitled "The management of acute venous thromboembolism in clinical practice – study rationale and protocol of the European PREFER in VTE Registry". *Thromb J* 2015; 13: 41.

Participation as co-investigator in the multicenter study entitled "Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study". *Int J Cardiol* 2018; 267: 68-73.

Participation as a member of the steering committee in the drafting of the Position Paper entitled: "Managing anticoagulation in the COVID-19 era between lockdown and reopening phases" promoted by the National Scientific Society FCSA (Federation of Centers for the diagnosis of thrombosis and the Surveillance of Anticoagulant therapies). *Intern Emerg Med* 2020; 15: 783-786.

Participation as co-investigator and head of the Hemostasis and Thrombosis Unit of the AOU Cagliari in the multicenter study "Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study". *Molecules* 2021; 26: 1425.

Participation as co-investigator and head of the Hemostasis and Thrombosis Unit of the AOU Cagliari in the multicenter study "Sex-based difference in anticoagulated patients with mechanical prosthetic heart valves and long-term mortality risk". *Int J Clin Pract* 2021; 75: e14064.

Participation as co-investigator and head of the Hemostasis and Thrombosis Unit of the AOU Cagliari in the multicenter study "Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study". *Molecules* 2021; 26: 1425.

Participation as co-investigator and head of the Hemostasis and Thrombosis Unit of the AOU Cagliari in the multicenter study "Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register". *Ther Adv Drug Saf* 2021;12: 20420986211062965.

Participation as a member of the steering committee in the drafting of the Position Paper entitled: "Management of DOAC in Patients Undergoing Planned Surgery or Invasive Procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA). Position Paper." promoted by the National Scientific Society FCSA (Federation of Centers for the Diagnosis of Thrombosis and the Surveillance of Anticoagulant Therapies). *Thromb Haemost* 2022; 122: 329-35.

Participation as a collaborator and head of the Hemostasis and Thrombosis Unit of the Cagliari University Hospital Company in the multicenter study entitled "The diagnostics of heparin induced thrombocytopenia in Italy and the possible impact of vaccine-induced immune thrombotic thrombocytopenia on it" coordinated by Prof. Paolo Gresele, Full Professor of Internal Medicine at the University of Perugia. *Clin Chem Lab Med* 2022; 61: e91-e95.

Participation as a member of the steering committee and responsible for the Haemostasis and Thrombosis Unit of the Cagliari University Hospital in the multicenter study promoted by the National Scientific Society FCSA (Federation of Centers for the diagnosis of thrombosis and the Surveillance of Anticoagulant therapies) entitled "Management of anticoagulation in hemodialysis: Results from a survey of current clinical practice in the Italian anticoagulation clinics". *Thromb Res* 2022; 220: 97-99.

Participation as a member of the steering committee and responsible for the Haemostasis and Thrombosis Unit of the Cagliari University Hospital in the multicenter study entitled "Descriptive analysis of patients positive for anti-phospholipid antibodies included in two Italian registries". *Bleeding, Thrombosis and Vascular Biology* 2023; 2: 92.

Participation as a collaborator and head of the Haemostasis and Thrombosis Unit of the Cagliari University Hospital in the multicenter study entitled "Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence". *Clin Chem Lab Med* 2024; 62: 1870-76.

International publications

1. **Barcellona D**, Biondi G, Vannini ML, Marongiu F. Comparison between recombinant and rabbit thromboplastin in the management of patients on oral anticoagulant therapy. *Thromb Haemost* 1996; 75: 488-90.
2. **Barcellona D**, Mameli G, Marongiu F. Inhibition of blood coagulation activation and oral anticoagulants in patients with mechanical heart valve prostheses. *Thromb Res* 1996; 81: 403-6.
3. Marongiu F, Biondi G, **Barcellona D**, Vannini ML, Balestrieri A. The old manual tilt tube thrombotest: still useful in the management of oral anticoagulants? *Thromb Res* 1996; 84: 379-84.
4. **Barcellona D**, Biondi G, Mameli G, Marongiu F. Are prothrombin fragment 1+2 and thrombin-antithrombin complexes useful in the management of oral anticoagulant therapy? *Int J Clin Lab Res* 1997; 27: 76-8.
5. Meloni L, **Barcellona D**, Marongiu F. Coagulation in chronic atrial fibrillation. *Circulation* 1997; 96: 1053-54.
6. **Barcellona D**, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or Acenocoumarol: Which Is better in the Management of Oral Anticoagulants? *Thromb Haemost* 1998; 80: 899-902.
7. **Barcellona D**, Contu P, Sorano GG, Pengo V, Marongiu F. The Management of Oral Anticoagulant Therapy: The Patient's Point of View. *Thromb Haemost* 2000; 83: 49-53.
8. **Barcellona D**, Contu P, Marongiu F. Patient education and oral anticoagulant therapy. *Haematologica* 2002; 87:1081-86.
9. **Barcellona D**, Fenu L, Cauli C, Pisu G, Marongiu F. Allele 4G of gene PAI-1 associated with prothrombin mutation G20210A increases the risk for venous thrombosis. *Thromb Haemost* 2003; 90: 1061-64.
10. Marongiu F, Fenu L, Pisu G, Contu P, **Barcellona D**. Hyperhomocysteinemia: could the post-methionine oral loading test sometimes be avoided? *Haematologica* 2003; 88: 186-91.
11. Prisco D, **Barcellona D**, Baudo F, Berrettini M, Ciavarella N, Cosmi B, Dettori AG, Finazzi G, Manotti C, Marongiu F, Moia M, Palareti G, Pengo V, Poli D, Testa S, Tositto A, Tripodi A. A guide to oral anticoagulant treatment. Recommendations of the Italian Federation of Anticoagulation Clinics (FCSA). *Haematologica* 2003; 88 (Suppl 2): 1-52. ISSN 1592-8721.

12. **Barcellona D**, Fenu L, Marongiu F. Oral anticoagulant therapy: should doctors change the way they give patients explanations? *Thromb Haemost* 2003; 90: 159-60.
13. Marongiu F, **Barcellona D**. The future of anticoagulation clinics a journey to thrombosis centers? *Haematologica* 2005; 90: 298.
14. **Barcellona D**, Fenu L, Minozzi M. Oral anticoagulant therapy and telemedicine. *Intern Emerg Med* 2006; 1: 166-67.
15. **Barcellona D**, Contu P, Marongiu F. A "two-step" educational approach for patients taking oral anticoagulants does not improve therapy control. *J Thromb Thrombolysis* 2006; 22: 185-190.
16. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Testa S, **Barcellona D**, Tripodi A on behalf of participating centres of Italian Federation of thrombosis Centres (FCSA). Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. *J Thromb Haemost* 2007; 5: 925-30.
17. Pengo V, Biasiolo A, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, **Barcellona D**, Tripodi A. A Comparison of Lupus Anticoagulant-Positive Patients With Clinical Picture of Antiphospholipid Syndrome and Those Without. *Arterioscler Thromb Vasc Biol* 2007; 27: e309-e310.
18. **Barcellona D**, Fenu L, Cornacchini S, Marongiu F. Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful? *Thromb Res* 2009; 123: 775-79.
19. Mameli A, **Barcellona Doris**, Marongiu Francesco. Rheumatoid arthritis and thrombosis. *Clin Exp Rheumatol* 2009; 27: 846-55.
20. Pengo V, Ruffatti A, Legnani C, Gresele P, **Barcellona D**, Erba N, Testa S, Marongiu F, Bison E, Denas G, Banzato A, Jose SP, Iliceto S. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. *J Thromb Haemost* 2010; 8: 237-42.
21. Pengo V, Denas G, Bison E, Banzato A, Jose SP, Gresele P, Marongiu F, Erba N, Veschi F, Ghirarduzzi A, De Candia E, Montaruli B, Marietta M, Testa S, **Barcellona D**, Tripodi A. Prevalence and significance of antiprothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). *Thromb Res* 2010; 126: 150-153.
22. Marongiu F, **Barcellona D**, Mameli A, Mariotti Stefano. Thyroid disorders and hypocoagulability. *Sem Thromb Hemost* 2011; 37: 11-16.
23. Mameli A, **Barcellona D**, Vannini ML, Marongiu F. High frequency of inadequate test requests for antiphospholipid antibodies in daily clinical practice. *Clin Chem Lab Med* 2011; 49: 695-98.
24. Mameli A, **Barcellona D**, Vannini ML, Marongiu F. A routine silica-based activated partial thromboplastin time (Hemosil aPTT-SP (TM)) mostly excludes the presence of lupus anticoagulant. *Int J Lab Hematol* 2011; 33: E12-E13.
25. **Barcellona D**, Fenu L, Vannini ML, Marongiu F, Piras M. Antiphospholipid syndrome patients: The performance of Coagucheck XS in the monitoring of Vitamin K-Antagonists. *Thromb Res* 2012; 129: e168-e170.
26. Angius G, **Barcellona D**, Cauli E, Meloni L, Raffo L. Myocardial infarction and antiphospholipid syndrome: A first study on finger PPG waveforms effects. In: *Computing in Cardiology 2012*; 39: 517-520.
27. **Barcellona D**, Fenu L, Cornacchini S, Marongiu F. Telemedicine can improve the quality of oral anticoagulation using portable devices and self-testing at home. *J Telemed Telecare* 2013; 19: 298-301.
28. Marongiu F, **Barcellona D**. Direct inhibitors of thrombin and factor Xa: the importance of laboratory skills. *Intern Emerg Med* 2013; 9: 897-98.
29. **Barcellona D**, Lizza M, Battino N, Fenu L, Marongiu F. The criteria of the Italian Federation of Thrombosis Centres on DOACs: a "real world" application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. *Intern Emerg Med* 2015; 10: 157-63.
30. Mameli A, **Barcellona D**, Marongiu F. Fatal Cytopenia Induced by Low-Dose Methotrexate in Elderly with Rheumatoid Arthritis. Identification of Risk Factors. *American J Ther* 2017; 24: e106-e107.

31. Porru M, Mameli A, Cianchetti ME, Musu M, Schirru P, Ruberto MF, **Barcellona D**, Marongiu F. Dabigatran overdose: a case report of acute hepatitis. Extracorporeal treatment. *Int J Hematol* 2017; 105: 532-535.
32. **Barcellona D**, Fenu L, Marongiu F. Point-of-care testing INR: an overview. *Clin Chem Lab Med* 2017; 55: 800-805.
33. Grandone E, **Barcellona D**, Colaizzo, D, Marongiu F. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients on oral anticoagulants. *J Endocrinol Inv* 2017; 40: 785-786.
34. Ruberto MF, Sorbello O, Civolani A, **Barcellona D**, Demelia L, Marongiu F. Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena. *Int J Lab Hematol* 2017; 39: 369-374.
35. **Barcellona D**, Mastino D, Marongiu F. Portable coagulometer for vitamin K-antagonist monitoring: the patients' point of view. *Patient Prefer Adherence* 2018; 12: 1521-26.
36. Ruberto MF, Marongiu F, Mandas A, Mameli A, Porru M, Cianchetti E, **Barcellona D**. The venous thromboembolic risk and the clot wave analysis: a useful relationship? *Clin Chem Lab Med* 2018; 56: 448-53.
37. Ruberto MF, Marongiu F, **Barcellona D**. Comparison of prothrombin time INR and clot waveform analysis performed with 129-mmol/L and 105-mmol/L citrate tubes. *Int J Lab Hematol* 2018; 40: 15-16.
38. **Barcellona D**, Fenu L, Marongiu F. Points of Care Testing International Normalized Ratio: Are They Useful for Monitoring Vitamin K Antagonists in a Thrombosis Center? *Point of Care* 2018; 17: 59-62.
39. Poli D, Antonucci E, Pengo V, Grifoni E, Maggini N, Testa S, Lodigiani C, Insana A, Marongiu F, **Barcellona D**, Paparo C, Bucherini E, Pignatelli P, Palareti G. Risk of reoperation in bioprosthetic valve patients with indication for long term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study. *Open Heart* 2018; 5: e000837.
40. Pengo V, Denas G, Zoppellaro G, Padayattil S, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, **Barcellona D**, Gerosa M, Banzato A. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. *Blood* 2018; 132: 1365-71.
41. Marongiu F, Barcellona D. Has time come for the use of direct oral anticoagulants in the extended prophylaxis of venous thromboembolism in acutely ill medical patients? *No. Intern Emerg Med* 2018; 13: 1015-18.
42. Marongiu F, **Barcellona D**. Direct oral anticoagulants: what can we learn? *Intern Emerg Med* 2018; 13: 989-92.
43. Grandone E, Ostuni A, Tiscia GL, Marongiu F, **Barcellona D**. Management of Patients Taking Oral Anticoagulants. Who Need Urgent Surgery for Hip Fracture. *Semin Thromb Hemost* 2019; 45: 164-70.
44. Marongiu F, Grandone E, **Barcellona D**. Pulmonary thrombosis in 2019-nCoV pneumonia? *J Thromb Haemost* 2020; 18: 1511-13.
45. **Barcellona D**, Favuzzi G, Vannini ML, Piras MS, Ruberto MF, Grandone E, Marongiu F. A Sardinian Family with Factor XI Deficiency. *Hamostaseologie* 2019; 39: 398-403.
46. Mameli A, Natale L, Musu M, Finco G, Pisanu A, Marongiu F, **Barcellona D**. Olanzapine-Associated Portal and Superior Mesenteric Vein Thrombosis. *Am J Ther* 2020; 27: e419-e420.
47. Ruberto MF, Marongiu F, Sorbello O, Civolani A, Demelia L, **Barcellona D**. Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? *Int J Lab Hematol* 2019; 41: 118-23.
48. Loddo A, Cornacchia S, Lo Cane F, **Barcellona D**, Marongiu F, Melis GB, Angioni S, Paolet AM, Neri M. Prophylaxis of peripartum haemorrhage using recombinant factor VIIa (rfVIIa) in pregnant women with congenital factor VII deficiency: a case report and literature review. *Eur J Obstet Gynecol Reprod Biol* 2019; 235: 77-80.

49. Mameli A, Schirru P, Porru M, Marongiu F, **Barcellona D**. Underuse of anticoagulant therapy in hospitalized older patients: comment on the article of Wojszel et al. *J Thromb Thrombolysis* 2020; 49: 136-37.
50. **Barcellona D**, Melis M, Floris G, Mameli A, Muroi A, Defazio G, Marongiu F. A "Catastrophic" Heparin-Induced Thrombocytopenia. *Case Rep Med* 2020; 2020: 6985020.
51. Saba L, Gerosa C, Fanni D, Marongiu F, La Nasa G, Caocci G, **Barcellona D**, Balestrieri A, Coghe F, Orrù G, Coni P, Piras M, Ledda F, Suri JS, Ronchi A, D'Andrea F, Cau R, Castagnola M, Faa G. Molecular pathways triggered by COVID-19 in different organs: ACE2 receptor-expressing cells under attack? A review. *Eur Rev Med Pharmacol Sci* 2020; 24: 12609-22.
52. Fanni D, Angotzi F, Gerosa C, **Barcellona D**, Senes G, Lai F, Martino G, Ascani S, Fanos V, Faa G. Multiple specialized stem cell niches characterize hematopoiesis in the human fetal liver. *Journal of Pediatric and Neonatal Individualized Medicine* 2020; 9: e090118.
53. **Barcellona D**, Marongiu F. The hemostatic system. 1ª Part. *Journal of Pediatric and Neonatal Individualized Medicine* 2020; 9: e090106.
54. Marongiu F, Grandone E, **Barcellona D**. Pulmonary thrombosis in 2019-nCoV pneumonia? *J Thromb Haemost* 2020; 18: 1511-13.
55. Poli D, Tosetto A, Palareti G, **Barcellona D**, Ciampa A, Grandone E, Manotti C, Moia M, Squizzato A, Toschi V, Testa S, On the behalf of Italian Federation of Anticoagulation Clinics (FCSA). Managing anticoagulation in the COVID-19 era between lockdown and reopening phases. *Intern Emerg Med* 2020; 15: 783-86.
56. Poli D, Antonucci E, Vignini E, Martines L, Testa S, Simioni P, Pengo V, Pignatelli P, Falanga A, Masciocco L, **Barcellona D**, Ciampa A, Chiarugi P, Paparo C, Ageno W, Palareti G, START2 Registry investigators. Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. *Eur J Intern Med* 2020; 80: 73-77.
57. **Barcellona D**, Marongiu F. Thrombosis centres and AVKs monitoring in COVID-19 pandemic. *Intern Emerg Med* 2020; 15: 1365-68.
58. Grandone E, Aucella F, **Barcellona D**, Brunoris G, Forneris G, Gresele P, Marietta M, Poli D, Testa S, Tripodi A, Genovesi SC. Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and Siset. *Blood Transfus* 2020; 18: 478-85.
59. Marongiu F, **Barcellona D**. Fondaparinux: Should It Be Studied in Patients with COVID-19 Disease? *TH Open* 2020; 4: e300-e302.
60. Costaggu D, Pinna E, Serchisu L, **Barcellona D**, Piano P, Ortu F, Marongiu F, Mandas A. The Repeatable Battery for the Assessment of Neuropsychological Status as a screening strategy for HIV-Associated Neurocognitive Disorders. *AIDS Care* 2021; 33: 357-63.
61. **Barcellona D**, Fanni D, Gerosa C, Congiu T, Orrù G, Faa G, Marongiu F. Heparins and 2019-nCoV infection: a narrative review. *Eur Rev Med Pharmacol Sci* 2021; 25: 3594-3606.
62. Marongiu F, Grandone E, Scano A, Orrù G, Marongiu S, Gerosa C, Fanni D, Faa G, **Barcellona D**. Infectious agents including COVID-19 and the involvement of blood coagulation and fibrinolysis. A narrative review. *Eur Rev Med Pharmacol Sci* 2021; 25: 3886-89.
63. Fanni D, Guido M, Gerosa C, Vallasca V, Moi M, Coni P, Vallebona E, van Eyken P, **Barcellona D**, Scano A, Orrù G, Pampaloni P, Castagnola M, Faa G. Liver changes in Wilson's disease: The full spectrum. A report of 127 biopsies from 43 patients. *Eur Rev Med Pharmacol Sci* 2021; 25: 4336-44.
64. Fanni D, Saba L, Demontis R, Gerosa C, Chighine A, Nioi M, Suri JS, Ravarino A, Cau F, **Barcellona D**, Botta MC, Porcu M, Scano A, Coghe F, Orrù G, Van Eyken P, Gibo Y, La Nasa G, D'Aloja E, Marongiu F, Faa G. Vaccine-induced severe thrombotic thrombocytopenia following COVID-19 vaccination: A report of an autoptoc case and review of the literature. *Eur Rev Med Pharmacol Sci* 2021; 25: 5063-69.
65. Ruberto MF, Piras MS, Sorbello O, Civolani A, Usai P, Fanni D, Orru G, Faa G, Marongiu F, **Barcellona D**. Chronic intravascular coagulation in liver cirrhosis predicts a high hemorrhagic risk. *Eur Rev Med Pharmacol Sci* 2021; 25: 5518-24.

66. Gerosa C, Faa G, Fanni D, Manchia M, Suri JS, Ravarino A, **Barcellona D**, Pichiri G, Coni P, Congiu T, Piras M, Cerrone G, Cau F, Ledda F, Aimola V, Coghe F, Porcu M, Cau R, Orru' G, Van Eyken P, La Nasa G, Castagnola M, Marongiu F, Saba L. Fetal programming of COVID-19: may the barker hypothesis explain the susceptibility of a subset of young adults to develop severe disease? *Eur Rev Med Pharmacol Sci* 2021; 25: 5876-84.
67. Fanni D, Cerrone G, Saba L, Demontis R, Congiu T, Piras M, Gerosa C, Suri J, Coni P, Caddori A, Piga M, Mancosu G, **Barcellona D**, Ravarino A, Chighine A, Cau F, Scano A, Balestrieri A. Thrombotic sinusoiditis and local diffuse intrasinusoidal coagulation in the liver of subjects affected by COVID-19: the evidence from histology and scanning electron microscopy. *Eur Rev Med Pharmacol Sci* 2021; 25: 5904-12.
68. Faa G, Gerosa C, Fanni D, **Barcellona D**, Cerrone G, Orrù G, Scano A, Marongiu F, Suri JS, Demontis R, Nioi M, D'Aloja E, La Nasa G, Saba L. Aortic vulnerability to COVID-19: is the microvasculature of vasa vasorum a key factor? A case report and a review of the literature. *Eur Rev Med Pharmacol Sci* 2021; 25: 6439-42.
69. Gerosa C, Faa G, Fanni D, Cerrone G, Suri JS, **Barcellona D**, Coni P, Congiu T, Lai ML, Piras M, Cau F, Coghe F, Balestrieri A, Cau R, Orru' G, Scano A, Van Eyken P, La Nasa G, Campagna M, Castagnola M, Gibo Y, Marongiu F, Saba L. Fetal programming of atherosclerosis: may the barker hypothesis explain the susceptibility of a subset of patients to develop stroke or cardiac infarct? *Eur Rev Med Pharmacol Sci* 2021; 25: 633-41.
70. Congiu T, Demontis R, Cau F, Piras M, Fanni D, Gerosa C, Botta C, Scano A, Chighine A, Faedda E, Cau R, Van Eyken P, Marongiu F, **Barcellona D**, Saba L, Orrù, G, Coghe F, Suri JS, Faa G, D'Aloja E. Scanning electron microscopy of lung disease due to covid-19 – a case report and a review of the literature. *Eur Review Med Pharmacol Sciences* 2021; 25: 7997-8003.
71. Grandone E, Aucella F, **Barcellona D**, Brunori G, Forneris G, Gresele P, Marietta M, Poli D, Testa S, Tripodi A, Genovesi S. Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Società Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Società Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET). *J Nephrol* 2021; 34: 31-38.
72. Pengo V, Hoxha Aa, Andreoli La, Tincani A, Silvestri E, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, **Barcellona D**, Gerosa M, Denas G. Trial of Rivaroxaban in AntiPhospholipid Syndrome (TRAPS): Two-year outcomes after the study closure. *J Thromb Haemost* 2021; 19: 531-35.
73. Marongiu F, Mameli A, Marongiu S, **Barcellona D**. Empathy and the Educational Approach to Patients with Atrial Fibrillation Treated with Direct Oral Anticoagulants. *Am J Ther* 2020; 28: e355-e357.
74. **Barcellona D**, Mameli A, Cornacchini S, Perra F, Diovaldi M, Farci N, Moledda V, Marongiu F. Patients' adherence to oral anticoagulants therapy: Comparison between vitamin K antagonists and direct oral anticoagulants. *Int J Cardiol* 2021; 333: 162-66.
75. Grandone E, Tiscia GL, Mastroianno M, Larciprete G, Kovac M, Tamborini Permunian E, Lojacono A, **Barcellona D**, Bitsadze V, Khizroeva J, Makatsarya A, Cacciola R, Martinelli I, Bucherini E, De Stefano V, Lodigiani C, Colaizzo D, De Lorenzo A, Piazza G, Margaglione M. Findings from a multicentre observational study on reproductive outcomes in women with unexplained recurrent pregnancy loss: the OTTILIA registry. *Hum Reprod* 2021; 36: 2083-90.
76. **Barcellona D**, Fenu L, Marongiu F. Clinical history and gastrointestinal bleeding in patients taking oral anticoagulants. *Int J Cardiol* 2021; 339: 134-37.
77. Marongiu F, Ntoukas DM, Barberini L, Ruberto MF, Piras MS, Conti M, Di Martino ML, Mura M, Marongiu S, Vannini ML, Lillu M, Piras M, Fanni D, Fenu L, Porcu C, **Barcellona D**, Faa G, Congiu T. Clot characterization by multidisciplinary approach: biochemical and imaging parameters in a hypocoagulative setting. A pilot study. *J Public Health Res* 2021;10: jphr.2021.2358.

78. Congiu T, Fanni D, Piras M, Gerosa C, Cau F, **Barcellona D**, D'Aloja E, Demontis R, Chighine F, Nioi M, Coni P, Ravarino A, Cerrone G, Aimola V, Botta C, Scano A, Orrù, G, Coghe F, Van Eyken P, La Nasa G, Saba L, Suri JS, Faa G, Marongiu F. Ultrastructural finding of lung injury due to Vaccine-induced Immuno Thrombotic Thrombocytopenia (VITT) following COVID-19 vaccination: a scanning electron microscopic study. *Eur Rev Med Pharmacol Sci* 2022; 26: 270-77.
79. Squizzato A, Poli D, **Barcellona D**, Ciampa A, Grandone E, Manotti C, Moia M, Toschi V, Tosetto A, Testa S, Scientific Reviewer Committee. Management of DOAC in Patients Undergoing Planned Surgery or Invasive Procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. *Thromb Haemost* 2022; 122: 329-35.
80. **Barcellona D**, Schirru P, Mameli A, Cornacchini S, Fenu L, Marongiu F. Over-anticoagulation by vitamin K antagonists and gender differences. *Int J Cardiol* 2022; 362: 147-51.
81. De Pascali F, Squizzato A, **Barcellona D**, Bucciarelli P, Ciampa A, Grandone E, Malcangi G, Rescigno G, Toschi V, Testa S, Poli D. Management of anticoagulation in hemodialysis: Results from a survey of current clinical practice in the Italian anticoagulation clinics. *Thromb Res* 2022; 220: 97-99.
82. Grandone E, **Barcellona D**, Intrieri M, Tiscia G, Nappi L, Othman M. The ART of Thromboprophylaxis in the Prevention of Gestational Venous Thromboembolism. *Semin Thromb Haemost* 2023; 49: 330-36.
83. Di Pino M, Ruberto MF, Costanzo G, Firinu D, Piras MS, Mura MN, Del Giacco S, Coghe F, Marongiu F, **Barcellona D**. Chronic spontaneous urticaria: a low-grade disseminated intravascular coagulation only partially reversed by Omalizumab. *Clin Exp Med* 2023; 23: 495-502.
84. Marongiu F, Marongiu S, Ruberto MF, Faa G, **Barcellona D**. Trace metals and the hemostatic system. *Clin Chim Acta* 2023; 547: 117458.
85. Marongiu F, Ruberto MF, Marongiu S, Matucci Cerinic M, **Barcellona D**. A journey to vasculopathy in systemic sclerosis: focus on haemostasis and thrombosis. *Clin Exp Med* 2023; 23: 4057-64.
86. Mameli A, Sestu A, Marongiu F, **Barcellona D**. Living on Oral Anticoagulants: Duke Anticoagulation Satisfaction Scale Results. *J Clin Med* 2023; 12: 7574.
87. Poli D, Tartaglia R, **Barcellona D**, Bucciarelli P, Ciampa A, Grandone E, Malcangi G, Rescigno G, Toschi V, Testa S, Squizzato A. Attitude to clinical research among health professionals affiliated with the Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA). *Bleeding, Thrombosis and Vascular Biology* 2023; 2: 59.
88. Marongiu F, Ruberto MF, Marongiu S, Mameli A, **Barcellona D**. Do we need more guidance on thrombophilia testing? Challenges and special considerations. *Expert Rev Hematol* 2024; 17: 27-37.
89. **Barcellona D**, Grandone E, Marongiu F. Hormones and thrombosis: the dark side of the moon. *Blood Transfus* 2024; 22: 46-54.
90. Galliazzo S, Bucciarelli P, **Barcellona D**, Ciampa A, Grandone E, Malcangi G, Rescigno G, Squizzato A, Toschi V, Testa S, Poli D. Practical Suggestions for an Optimal Management of Vitamin K Antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper. *Thromb Haemost* 2024; 124: 803-809.
91. **Barcellona D**, Marongiu F, Grandone E. Contraceptives and Thrombosis: An Intertwined Revolutionary Road. *Semin Thromb Hemost* 2024; 50: 91-95.
92. Marongiu F, **Barcellona D**. Why Does Rivaroxaban Not Work in Severe Mitral Stenosis? *Semin Thromb Hemost* 2024; 50: 303-306.
93. Marongiu F, Ruberto MF, **Barcellona D**. Is anticoagulative therapy in systemic sclerosis to be reconsidered? *J Scleroderma Relat Disord* 2024; 9: 81-85.

94. Grandone E, Tiscia GL, Ostuni A, Marongiu F, **Barcellona D**. Navigating anemia and anticoagulation in elderly patients undergoing orthopedic surgery: strategies for preventing complications and implementing treatments. *Blood Transfus* 2024; 22: 450-58.
95. Marongiu F, Ruberto MF, Marongiu S, **Barcellona D**. Clot Waveform Analysis. From Hypercoagulability to Hypocoagulability – A Review. *Arch Pathol Lab Med* 2024; 148: 1371-75.
96. **Barcellona D**, Schirru P, Marongiu S, Marongiu F. The hemostatic system. 2nd Part. *Journal of Pediatric and Neonatal Individualized Medicine* 2024; 13: e130117.
97. Marongiu F, Grandone E, Marongiu S, Mameli A, **Barcellona D**. Stroke in women: anticoagulation in a complicated puzzle. *Bleeding, Thrombosis and Vascular Biology* 2024; 3: 137.
98. Mameli A, Marongiu F, Fenu L, Ruberto MF, Schirru P, Cornacchini S, **Barcellona D**. The Role of the Hemostasis and Thrombosis Unit in the Management of the Patients with Acquired Hemophilia. *Turk J Haematol* 2024; 41: 264-70.
99. Aiello A, Sarti L, Sandri G, Poli D, Sivera P, Barcellona D, Prisco D, Pizzini AM, Vercillo G, Antonucci E, Palareti G, Pengo V; Start2 Antiphospholipid Registry collaborators. Impact of the 2023 ACR/EULAR Classification Criteria on START2 Antiphospholipid Registry. *Int J Lab Hematol* 2024 Dec 11. doi: 10.1111/ijlh.14416.

Chapter in book

1. Marongiu F, **Barcellona D**. Vitamin K antagonists (coumarins), drugs used in the prevention and treatment of cardioembolism, deep vein thrombosis, and pulmonary embolism. In: Kiran S. Panickar et al. *Bioactive Nutraceuticals and Dietary Supplements in Neurological and Brain Disease: Prevention and Therapy* 2014; p. 395-398, Amsterdam: Elsevier, ISBN: 9780124115293, doi: 10.1016/B978-0-12-411462-3.00040-0.
2. Ruberto MF, Marongiu F, **Barcellona D**. Performance and Interpretation of Clot Waveform Analysis. In: Emmanuel J. Favalaro Robert C. Gosselin. *Hemostasis and Thrombosis. Methods and Protocols. Second Edition. Methods Mol Biol* 2023; 2663: 163-173, NEW YORK: Humana Press, ISBN: 978-1-0716-3174-4. ISSN: 1940-6029, doi: 10.1007/978-1-0716-3175-1_94.

Affiliation of Scientific Societies and related positions held

Member of the National Scientific Society FCSA (Federations of Centers for the diagnosis of thrombosis and the Surveillance of Antithrombotic Therapies) from September 1992 to date.

Councilor of the National Director Committee of FCSA from October 2018 to September 2021. Re-elected Councilor of the National Director Committee of FCSA for the three-year period 2021-2024 on 17 September 2021.

Ordinary member of the Italian Society for the Study of Hemostasis and Thrombosis (SISSET) from 07.06.2020 to date.

Appointed by the President Prof. Domenico Prisco, Regional Representative of SISSET for Sardinia in the three-year period from 2008 to 2010.

From 5 November 2022, elected to the National Executive Committee of SISSET for the two-year period 2023-2024.

From February 2020 to November 2022, appointed by the President (Prof. Paolo Gresele) and the Board of Directors of the Italian Society for the Study of Haemostasis and Thrombosis (SISSET), member of the CEET Commission (Expert Commission on Haemostasis and Thrombosis).

Subsequently, confirmed as a member of the CEET by the President (Prof. Valerio De Stefano) and the Board of Directors of SISSET for the two-year period 2023-2024.

Member of the International Society on Thrombosis and Haemostasis (ISTH) from 12 July 2020 to date.

Ordinary member of the Italian Society of Internal Medicine (SIMI) from 01/21/2021 to 12/31/2024.

Collaboration as a reviewer with international scientific journals indexed on Scopus and/or Web of Science e su JCR

Rated as Q1 on SJR:

Frontiers in Medicine (2023)
Frontiers in Cardiovascular Medicine (2023)
Journal of Clinical Medicine (2020-2022),
Journal of Telemedicine and Telecare (2014),
Drug Safety (2019),
Biomedicines (2021),
Patient Preference and Adherence (2017),
Blood Transfusion (2020),
American Journal of Cardiovascular Drugs (2018).

Rated as Q2 on SJR:

Science Progress (2020).
Internal and Emergency Medicine (2018-2019-2020),
Thrombosis Research (2012),
Clinical Drug Investigation (2019),
World Journal of Surgical Oncology (2020),
Medicina-Lithuania (2021).
Expert Review of Cardiovascular Therapy (2015-2020).

Rated as Q3 on SJR:

Case Report in Cardiology (2018).
Drug, Healthcare and Patient Safety (2017).

Rated as Q4 on SJR:

Journal of Pediatric and Neonatal Individualized Medicine (JPNIM) (2020-2021).

Participation in editorial boards of scientific journals

From 2014 to date, member of the Editorial Board of the Portal of anticoagulant and antithrombotic treatments "Anticoagulazione.it" owned by Fondazione Arianna Anticoagulazione, President Prof. Gualtiero Palareti.

From April 2019, member by invitation of the Editorial Board of the scientific Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). ISSN 2281-0692. I.F.= 0.162.

From May 2020 to date, Associate Editors by invitation of the scientific journal "Journal of Public Health Research". ISSN 2279-9036.

From June 2020 to date, member by invitation of the Topical Advisory Panel of the scientific journal "Medicina (Lithuania)". ISSN 1648-9144. IF = 2.948.

From 22 April 2022 to date, by invitation, member of the Editorial Board as Review Editor for thrombosis for the scientific journal Frontiers in Cardiovascular Medicine. ISSN 2297- 055X. IF = 2.8.

Healthcare activity

From October 1992 to November 1997, ordinary and on-call healthcare activity, as a doctor I specialist training, at the Medical Clinic "Mario Aresu" of the University of Cagliari, Director Prof. Angelo Balestrieri.

From December 1997 to February 2000, ordinary healthcare activity, as an internal physician, at the UOC of Internal Medicine and Hemocoagulopathies directed by Prof. Francesco Marongiu.

From March 2000 to February 2002, ordinary and on-call healthcare activity, as a doctor on contract in a private practice, at the UOC of Internal Medicine and Hemocoagulopathies directed by Prof. Francesco Marongiu.

From March 16, 2002 to September 26, 2018, as a University Researcher, in agreement as a First level Medical Director, at the UOC of Internal Medicine and Hemocoagulopathies directed by Prof. Francesco Marongiu, healthcare activity structured as follows:

- a) clinical activity and internal medicine on-call service at the Internal Medicine Department for highly complex patients,
- b) outpatient activity at the Haemostasis and Thrombosis Center for patients with thromboembolic diseases and treated with anticoagulants, for patients with congenital or acquired thrombophilia and for haemophilic patients with congenital defects of plasma coagulation factors,
- c) consultancy activity for patients hospitalized in other departments and referred to the Emergency Department of the University Hospital of Cagliari and for patients hospitalized in other city hospitals.

From 27 September 2018 to date, Director of the Simple Departmental Structure of Haemostasis and Thrombosis, consisting of the Haemostasis and Thrombosis Center and four ordinary hospitalization beds, belonging to the DAI of Specialist Medicine, resolution no. 1030 adopted by the General Director of the AOU of Cagliari on 27.09.2018.